Priority 2 from the Myeloma (Canada) PSP
| UNCERTAINTY: Are novel immunotherapies (e.g., CAR T) effective for the treatment of myeloma? (JLA PSP Priority 2) | |
|---|---|
| Overall ranking | 2 |
| JLA question ID | 0113/2 |
| Explanatory note | In the absence of a cure, people affected by myeloma would like to see new treatments for myeloma. Specifically, participants pointed to novel immunotherapies as a promising area of research that they would like to be explored. Indeed, many participants were wondering about the effectiveness of chimeric antigen receptor therapy (CAR T), and the role that this treatment will have for future treatment of myeloma. |
| Evidence |
No evidence identified |
| Health Research Classification System category | Cancer and neoplasms |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | I'd like to see if CAR-T cell therapy would be effective in treating myeloma. ~ More research and access to immunotherapy. ~ Possible immunotherapy treatment options ~ The effectiveness of Cart-Tcells treatment. ~ Would BCMA CAR T-cells be more effective in earlier lines of therapy? ~ More novel and targeted therapies eg Car-T cell. ~ Immunotherapy or other experimental treatments |
| Submitted by | Please see the PSP Engagement Summary on the JLA website |
| PSP information | |
|---|---|
| PSP unique ID | 0113 |
| PSP name | Myeloma (Canada) |
| Total number of uncertainties identified by this PSP. | 59 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 28 April 2021 |